Stephanie Schonewald, PhDView Public Profile
Dr. Stephanie Schonewald is a Partner at Choate, where she counsels biotech and pharmaceutical companies on the strategic development of patent portfolios, patent prosecution, and post-grant patent challenges.
Stephanie advises clients who are involved in contentious patent scenarios. She has handled a variety of third party submissions, protests, and post-grant proceedings before the United States Patent and Trademark Office (USPTO). She has worked on over 55 inter partes review, post grant review, and covered business method review proceedings before the Patent Trial and Appeal Board (PTAB).
Stephanie also advises clients on the management of their US patent office activity alongside other global patent activity. For example, she routinely consults with clients on European third party observations and oppositions. She has also consulted with clients on post-grant challenges in other key jurisdictions, including Australia and Japan.
Stephanie’s skills in managing patent disputes were developed, in part, through her district court patent litigation experience. She has litigated and advised clients regarding complex patent infringement and validity issues in a variety of jurisdictions across the country.
Stephanie’s clients include Regeneron Pharmaceuticals, Inc., Foundation Medicine, Inc., BioNTech SE, Akouos, Inc., Momenta Pharmaceuticals, Inc., Progenics Pharmaceuticals, and Saudi Arabian Oil Company.
Sessions with Stephanie Schonewald, PhD
01:00 PM EST
January 27, 2022
The USPTO has recently released a third report providing data on post-grant petitions filed at the PTAB against Orange Book and biologic patents. Although the report shows that such petitions represent only a small number of the petitions filed at the PTAB, namely 4% challenging Orange Book patents, and 2% challenging biologic patents, these IPRs challenge patents of high value. …